Varenicline in the treatment of tobacco dependence

References

• [APA] American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders20004Washington DCAmerican Psychiatric Association
   Google Scholar
• American Lung AssociationTrends in tobacco use2007 [online]. Accessed 23 July 2007. URL: http://www.lungusa.org/site/apps/s/content.asp?c=dvLUK9O0E&b=34706&ct=67648
   Google Scholar
• AubinH-JBobakABrittonJRVarenicline versus transdermal nicotine patch for smoking cessation: results from a randomised, open-label trialThorax2008 8 February 2008; [Epub ahead of print]10.1136/thx.2007.090647
   Web of Science ®Google Scholar
• BalfourDJKThe neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus accumbensNicotine Tob Res2004689991215801566
   PubMed Web of Science ®Google Scholar
• BenowitzNLPharmacology of nicotine: addiction and therapeuticsAnnu Rev Pharmacol Toxicol1996365976138725403
   PubMed Web of Science ®Google Scholar
• BenowitzNLPorchetHJacobP3rdNicotine dependence and tolerance in man: pharmacokinetic and pharmacodynamic investigationsProg Brain Res198979279872587748
   PubMed Web of Science ®Google Scholar
• BursteinAHFullertonTClarkDJPharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokersJ Clin Pharmacol20064612344017050788
   PubMed Web of Science ®Google Scholar
• BustoUKaplanHLZawertailoLPharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humansClin Pharmacol Ther199455451638162672
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and PreventionAnnual smokingattributable mortality, years of potential life lost, and productivity losses – United States, 1997–2001MMWR Morb Mortal Wkly Rep200554625815988406
   PubMedGoogle Scholar
• Centers for Disease Control and PreventionCigarette smoking among adults – United States, 2007MMWR Morb Mortal Wkly Rep20075611576117989644
   PubMedGoogle Scholar
• CoeJWBrooksPRVetelinoMGVarenicline: an α4β2 nicotinic receptor partial agonist for smoking cessationJ Med Chem2005483474715887955
   PubMed Web of Science ®Google Scholar
• CohenCPerraultGVoltzCSR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in ratsBehav Pharmacol2002134516312394421
   PubMed Web of Science ®Google Scholar
• CohenCPerraultGGriebelGNicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: Reversal by the cannabinoid (cb1) receptor antagonist, rimonabant (sr141716)Neuropsychopharmacology2005301455515292905
   PubMed Web of Science ®Google Scholar
• CritchleyJACapewellSMortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic reviewJAMA2003290869712837716
   PubMed Web of Science ®Google Scholar
• [EMEA] European Medicines AgencyPress Release. European Medicines Agency concludes new advice to doctors and patients for Champix needed2007 [online]. Accessed 12 March 2008. URL: http://www.emea.europa.eu/pdfs/general/direct/pr/59551607en.pdf
   Google Scholar
• EtterJ-FCytisine for smoking cessation: a literature review and meta-analysisArch Intern Med20061661553916908787
   PubMed Web of Science ®Google Scholar
• FaesselHMSmithBJGibbsMASingle-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokersJ Clin Pharmacol200646991816920893
   PubMed Web of Science ®Google Scholar
• FagerströmKOSchneiderNGMeasuring nicotine dependence in tobacco smoking: a review of the Fagerström Tolerance QuestionnaireJ Behav Med198912159822668531
   PubMed Web of Science ®Google Scholar
• FagerströmKOBalfourDJKNeuropharmacology and potential efficacy of new treatments for tobacco dependenceExpert Opin Investig Drugs20061510716
   PubMed Web of Science ®Google Scholar
• FagerströmKOJimenez-RuizCAAstray MochalesJCan smoking for positive or negative reinforcement together with dependence help us better diagnose smokers?J Smoking Cessation2007257
   Google Scholar
• [FDA] Food and Drug Administration2007a NDA 21–888. Zimulti (rimonabant) Tablets, 20 mg. Sanofi Aventis. Advisory Committee – June 13, 2007 [online]. Accessed 2 Oct 2007. URL: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4306b1-fda-backgrounder.pdf
   Google Scholar
• [FDA] Food and Drug AdministrationEarly communication about an ongoing safety review: Varenicline (marketed as Chantix)2007b [online]. Accessed 14 Jan 2008. URL: http://www.fda.gov/cder/drug/early_comm/varenicline.htm
   Google Scholar
• FensterCPRainsMFNoeragerBInfluence of subunit composition on desensitization of neuronal acetylcholine receptors at low concentrations of nicotineJ Neurosci1997175747599221773
   PubMed Web of Science ®Google Scholar
• FioreMCBaileyWCCohenSJTreating tobacco use and dependence. Clinical Practice Guideline2000 [online]. Accessed 13 Feb 2007. URL: http://www.surgeongeneral.gov/tobacco/treating_tobacco_use.pdf
   Google Scholar
• FouldsJThe neurobiological basis for partial agonist treatment of nicotine dependence: vareniclineInt J Clin Pract200660571616700857
   PubMed Web of Science ®Google Scholar
• FouldsJGandhiKKSteinbergMBFactors associated with quitting smoking at a tobacco dependence treatment clinicAm J Health Behav2006304001216787130
   PubMed Web of Science ®Google Scholar
• GonzalesDRennardSINidesMVarenicline, and α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trialJAMA2006296475516820546
   PubMed Web of Science ®Google Scholar
• HeathertonTFKozlowskiLTFreckerRCThe Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance QuestionnaireBr J Addict1991861119271932883
   PubMedGoogle Scholar
• HechtSSCigarette smoking and lung cancer: chemical mechanisms and approaches to preventionLancet Oncol20023461912147432
   PubMed Web of Science ®Google Scholar
• HenningfieldJEKeenanRMNicotine delivery kinetics and abuse liabilityJ Consult Clin Psychol199361743508245272
   PubMed Web of Science ®Google Scholar
• HoffmannDHoffmannIEl-BayoumyKThe less harmful cigarette: a controversial issue. A tribute to Ernst L. WynderChem Res Toxicol2001147679011453723
   PubMed Web of Science ®Google Scholar
• HughesJSteadLLancasterTAntidepressants for smoking cessationCochrane Database Syst Rev2004CD00003115494986
   PubMed Web of Science ®Google Scholar
• HughesJREffects of abstinence from tobacco: valid symptoms and time courseNicotine Tob Res200793152717365764
   PubMed Web of Science ®Google Scholar
• HylandALiQBauerJEPredictors of cessation in a cohort of current and former smokers followed over 13 yearsNicotine Tob Res20046Suppl 3S363915799599
   PubMed Web of Science ®Google Scholar
• JasinskiDRPevnickJSGriffithJDHuman pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addictionArch Gen Psychiatry19783550116215096
   PubMed Web of Science ®Google Scholar
• JasinskiDRPrestonKLAssessment of dezocine for morphine-like subjective effects and miosisClin Pharmacol Ther19853854482865027
   PubMed Web of Science ®Google Scholar
• JorenbyDEHaysJTRigottiNAEfficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trialJAMA2006296566316820547
   PubMed Web of Science ®Google Scholar
• KelleyAENicotinic receptors: addiction’s smoking gun?Nat Med20028447911984581
   PubMed Web of Science ®Google Scholar
• LindblomNde VilliersSHLKalayanovGActive immunization against nicotine prevents reinstatement of nicotine-seeking behavior in ratsRespiration2002692546012097770
   PubMed Web of Science ®Google Scholar
• MackayJEriksenMShafeyOThe Tobacco Atlas20062Atlanta, Georgia, USAAmerican Cancer Society
   Google Scholar
• MarubioLMGardierAMDurierSEffects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptorsEur J Neurosci20031713293712713636
   PubMed Web of Science ®Google Scholar
• McCollSBursteinAReevesKHuman abuse liability of the smoking cessation drug varenicline in smokers and nonsmokersClin Pharmacol Ther2008 February 20 2008; [Epub ahead of print]10.1038/sj.clpt.6100510
   Web of Science ®Google Scholar
• NakamuraMOshimaAFujimotoYEfficacy and safety of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokersClin Ther20072910405617692720
   PubMed Web of Science ®Google Scholar
• NidesMGloverEReusVVarenicline versus bupropion for smoking cessation: A pooled analysisAm J Health Behav2008326647518442345
   PubMed Web of Science ®Google Scholar
• NidesMOnckenCGonzalesDSmoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-upArch Intern Med20061661561816908788
   PubMed Web of Science ®Google Scholar
• NuttDKingLASaulsburyWDevelopment of a rational scale to assess the harm of drugs of potential misuseLancet200736910475317382831
   PubMed Web of Science ®Google Scholar
• ObachRSReed-HagenAEKruegerSSMetabolism and disposition of varenicline, a selective α4β2 acetylcholine receptor partial agonist, in vivo and in vitroDrug Metab Dispos2006341213016221753
   PubMed Web of Science ®Google Scholar
• OnckenCGonzalesDNidesMEfficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessationArch Intern Med20061661571716908789
   PubMed Web of Science ®Google Scholar
• PabrezaLADhawanSKellarKJ[3h]cytisine binding to nicotinic cholinergic receptors in the brainMol Pharmacol1991399121987453
   PubMed Web of Science ®Google Scholar
• Pfizer IncChantix™ (varenicline) tablets prescribing information drug insert2008New York, NY, USAPfizer Inc
   Google Scholar
• Pfizer LtdChampix™ summary of product characteristics2007UK
   Google Scholar
• PicciottoMRZoliMChangeuxJPUse of knock-out mice to determine the molecular basis for the actions of nicotineNicotine Tob Res19991Suppl 2S1215 discussion S139–40.11768168
   PubMedGoogle Scholar
• PidoplichkoVINoguchiJAreolaOONicotinic cholinergic synaptic mechanisms in the ventral tegmental area contribute to nicotine addictionLearn Mem20041160914747518
   PubMed Web of Science ®Google Scholar
• PomerleauOFFagerströmKMarksJLDevelopment and validation of a self-rating scale for positive- and negative-reinforcement smoking: the Michigan Nicotine Reinforcement QuestionnaireNicotine Tob Res20035711814577987
   PubMed Web of Science ®Google Scholar
• RollemaHChambersLKCoeJWPharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aidNeuropharmacology2007a529859417157884
   PubMed Web of Science ®Google Scholar
• RollemaHCoeJWChambersLKRationale, pharmacology and clinical efficacy of partial agonists of α4β2 nAHc receptors for smoking cessationTrends Pharmacol Sci2007b283162517573127
   PubMed Web of Science ®Google Scholar
• RussellMAHWonnacottSRussellMAHStolemanIPNicotine intake and its control over smokingNicotine psychopharmacology1990Oxford, U.KOxford University Press374418
   Google Scholar
• SilagyCLancasterTSteadLNicotine replacement therapy for smoking cessationCochrane Database Syst Rev2004CD00014615266423
   PubMedGoogle Scholar
• SlemmerJEMartinBRDamajMIBupropion is a nicotinic antagonistJ Pharmacol Exp Ther20002953212710991997
   PubMed Web of Science ®Google Scholar
• StapletonJAWatsonLSpirlingLIVarenicline in the routine treatment of tobacco dependence: a pre – post comparison with nicotine replacement therapy and an evaluation in those with mental illnessAddiction20081031465418028247
   PubMed Web of Science ®Google Scholar
• SuiECKTyndaleRFNon-nicotinic therapies for smoking cessationAnn Rev Pharmacol Toxicol2007475416417209799
   PubMed Web of Science ®Google Scholar
• SutherlandGStapletonJARussellMAHRandomised controlled trial of nasal nicotine spray in smoking cessationLancet1992340324291353803
   PubMed Web of Science ®Google Scholar
• TerresWBeckerPRosenbergAChanges in cardiovascular risk profile during the cessation of smokingAm J Med19949724298092173
   PubMed Web of Science ®Google Scholar
• TønnesenPCarrozziLFagerströmKSmoking cessation in patients with respiratory diseases: a high priority, integral component of therapyEur Respir J20072939041717264326
   PubMed Web of Science ®Google Scholar
• TonstadSTønnesenPHajekPEffect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trialJAMA2006296647116820548
   PubMed Web of Science ®Google Scholar
• TsaiS-TChoH-JChengH-SA randomized, placebocontrolled trial of varenicline, a selective α4β2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokersClin Ther20072910273917692719
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human ServicesThe Health Consequences of Smoking. Nicotine Addiction1988Rockville, MarylandA Report of the Surgeon General
   Google Scholar
• WestRUssherMEvansMAssessing DSM-IV nicotine withdrawal symptoms:a comparison and evaluation of five different scalesPsychopharmacology (Berl)20061846192716308727
   PubMed Web of Science ®Google Scholar
• WewersMEStillmanFAHartmanMSDistribution of daily smokers by stage of change: Current Population Survey resultsPrev Med2003367102012744915
   PubMed Web of Science ®Google Scholar
• WilliamsKEReevesKBillingCBJrA double-blind study evaluating the long-term safety of varenicline for smoking cessationCurr Med Res Opin20072379380117407636
   PubMed Web of Science ®Google Scholar